AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 SEP 4 - (NewsRx.com & NewsRx.net) -- A model for radioimmunotherapy of ovarian cancer micrometastases has been developed.
"A simple model has been developed to investigate the dosimetry of micrometastases in the peritoneal cavity during intraperitoneal targeted liposomal radioimmunotherapy. The model is applied to free-floating tumors with radii between 0.005 cm and 0.1 cm," scientists in Canada report.
"Tumor dose is assumed to come from two sources: free liposomes in solution in the peritoneal cavity and liposomes bound to the surface of the micrometastases. It is assumed that liposomes do not penetrate beyond the surface of the tumors and that the total amount of surface antigen does not change over the course of treatment," wrote A.M. Syme and colleagues, University of Alberta, Department of Physics.
"Integrated tumor doses are expressed as a function of biological parameters that describe the rates at which liposomes bind to and unbind from the tumor surface, the rate at which liposomes escape from the peritoneal cavity and the tumor surface antigen density," the researchers wrote.
"Integrated doses are translated into time-dependent tumor control probabilities (TCPs). The results of the work are illustrated in the context of a therapy in which liposomes labeled with Re-188 are targeted at ovarian cancer cells that express the surface antigen CA-125," the researchers stated.
"The time required to produce a TCP of 95% is used to investigate the importance of the various parameters. The relative contributions of ...